Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.37
-0.03 (-0.15%)
At close: Aug 10, 2026, 4:00 PM EDT
20.30
-0.07 (-0.34%)
After-hours: Aug 10, 2026, 7:34 PM EDT
Syndax Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 336.48 | 134.93 | 154.08 | 295.39 | 74.36 | 221.97 |
Short-Term Investments | 217.79 | 278.76 | 428.83 | 282.19 | 410.04 | 224.87 |
Cash & Short-Term Investments | 554.27 | 413.69 | 582.91 | 577.58 | 484.4 | 446.83 |
Cash Growth | 18.25% | -29.03% | 0.92% | 19.24% | 8.41% | 52.47% |
Accounts Receivable | 45.07 | 38 | 7.6 | - | - | - |
Other Receivables | 25.06 | 30.15 | 3.64 | - | 3.47 | - |
Total Trade Receivables | 70.13 | 68.15 | 11.24 | - | 3.47 | - |
Inventory | 33.16 | 32.75 | 0.37 | - | - | - |
Other Current Assets | 17.48 | 13.5 | 8.54 | 3.29 | 1.92 | 1.57 |
Total Current Assets | 675.04 | 528.08 | 603.06 | 580.88 | 489.79 | 448.4 |
Net Property, Plant & Equipment | 1.29 | 1.52 | 2.02 | 1.5 | 1.06 | 1.26 |
Long-Term Investments | 27.22 | - | 119.52 | 29.83 | 5.47 | - |
Other Long-Term Assets | 0.1 | 0.1 | 0.22 | 0.68 | 0.92 | - |
Total Assets | 703.65 | 529.71 | 724.82 | 612.88 | 497.24 | 449.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.87 | 16.58 | 11.63 | 9.96 | 4.35 | 5.67 |
Accrued Expenses | 94.3 | 103.06 | 60.1 | 39.86 | 24.28 | 14.47 |
Current Portion of Leases | 0.51 | 0.47 | 0.48 | 1.05 | 0.44 | 0.36 |
Other Current Liabilities | - | - | 31.35 | 7.23 | - | 0.19 |
Total Current Liabilities | 99.68 | 120.12 | 103.55 | 58.1 | 29.07 | 20.68 |
Long-Term Debt | 244.09 | - | - | - | - | 19.9 |
Long-Term Leases | 0.76 | 1.05 | 1.58 | 0.59 | 0.72 | 0.71 |
Other Long-Term Liabilities | 344.03 | 343.91 | 331.57 | - | - | - |
Total Long-Term Liabilities | 588.88 | 344.96 | 333.14 | 0.59 | 0.72 | 20.61 |
Total Liabilities | 688.55 | 465.08 | 436.69 | 58.68 | 29.79 | 41.29 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,614 | 1,571 | 1,509 | 1,456 | 1,161 | 952.02 |
Accumulated Other Comprehensive Income | -0.14 | 0.45 | 0.16 | 0.22 | -0.81 | 0.05 |
Retained Earnings | -1,599 | -1,507 | -1,221 | -902.4 | -693.04 | -543.7 |
Shareholders' Equity | 15.1 | 64.63 | 288.12 | 554.2 | 467.45 | 408.37 |
Total Liabilities & Equity | 703.65 | 529.71 | 724.82 | 612.88 | 497.24 | 449.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 245.36 | 1.52 | 2.06 | 1.64 | 1.16 | 20.97 |
Net Cash (Debt) | 308.91 | 412.16 | 580.86 | 575.95 | 483.24 | 425.86 |
Net Cash Growth | -33.86% | -29.04% | 0.85% | 19.19% | 13.47% | 56.26% |
Net Cash Per Share | 3.52 | 4.76 | 6.78 | 8.19 | 7.95 | 7.94 |
Book Value | 15.1 | 64.63 | 288.12 | 554.2 | 467.45 | 408.37 |
Book Value Per Share | 0.17 | 0.75 | 3.37 | 7.88 | 7.69 | 7.62 |
Tangible Book Value | 15.1 | 64.63 | 288.12 | 554.2 | 467.45 | 408.37 |
Tangible Book Value Per Share | 0.17 | 0.75 | 3.37 | 7.88 | 7.69 | 7.62 |